In FSHD, interventions that would restore the actin–myosin interface or regulate calcium entry might represent novel therapeutic options to reduce muscle weakness in FSHD and pave the way to therapies to improve muscle function and the life of patients. This evidence concerns the gene MYH14 and Facioscapulohumeral dystrophy.